Accelerated Biological Aging is Associated With Increased Risk of T2DM in the MASLD Population

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age20-90
SponsorNingbo No. 1 Hospital

About this trial

The association between biological aging and type 2 diabetes mellitus (T2DM) incidence in individuals with and without metabolic dysfunction-associated steatotic liver disease (MASLD) remains unclear.We assessed biological age by calculating phenotypic age (PhenoAge), Klemera-Doubal method (KDMAge), and homeostatic dysregulation (HDAge). To examine the association of biological ageing with the risk of T2DM, cox regression models were conducted. Furthermore, we applied survival analysis, restricted cubic spline models and population attributable fraction (PAF) to further evaluate the association between biological ageing and T2DM incidence.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Abdominal ultrasound data available in annual health check-up records

Disqualifiers

Age <20 or >90 years

Other causes of hepatic steatosis (e.g., alcoholic liver disease or hepatitis B infection)

Type 2 diabetes mellitus at baseline

Missing baseline data for any of the following variables: systolic blood pressure, albumin, alkaline phosphatase, blood urea nitrogen, creatinine, glycated hemoglobin (HbA1c), total cholesterol, lymphocyte percentage, white blood cell count, mean corpuscular volume, uric acid, fasting plasma glucose, and red cell distribution width (RDW)

Trial population

This retrospective cohort study is based on physical examination at the Physical Examination Center of The First Affiliated Hospital of Ningbo University and included participants aged 20 to 90 years. Individuals included had available abdominal ultrasound data and at least one recorded metabolic indicator per year. Participants with type 2 diabetes at baseline or with other causes of hepatic steatosis were excluded. The study population was categorized into MASLD and non-MASLD groups for comparative analysis.

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • Observational

    Other intervention

    Observational

Treatment groups

2,720 Participants
are divided into 2 treatment groups
Group A: MASLD group1 intervention
Group B: non-MASLD group1 intervention

Trial outcomes

Primary outcomes

1

Incidence of onset T2DM

Time frame
through study completion, an average of 3 year

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.